CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
TUCSON, Ariz., July 18, 2017 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2017 second quarter financial results after market close on Tuesday, August 8, 2017. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Tuesday, August 8 to discuss these results and answer questions.
Individuals interested in listening to the conference call may do so by dialing (866) 394-4225 for domestic callers, or (678) 509-7535 for international callers (conference ID: 55006903), or from the webcast on the “Investors” section of the Company’s website at: www.htgmolecular.com. The webcast will be available on the Company’s website for 90 days following the completion of the call.
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. In 2013 the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Contact: Westwicke Partners Jamar Ismail Phone: (415) 513-1282 Email: [email protected] TJ Johnson President / CEO HTG Molecular Diagnostics Phone: (520) 547-2827 x130 Email: [email protected]
